Understanding the experiences of multiple myeloma patients treated with CAR T-cell therapy
Official title: Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10934071 · Data updated 2026-11-12
This study is looking at how patients with relapsed or hard-to-treat multiple myeloma feel and do after receiving CAR T-cell therapy, aiming to understand their health and emotional well-being to help improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $691,118 |
| NIH project number | 1R01CA281756-01A1 |
| Project ID | NIH-10934071 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with relapsed or refractory multiple myeloma who are receiving CAR T-cell therapy.
✕Less likely to help
Patients who are not undergoing CAR T-cell therapy or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the experiences of patients with relapsed or refractory multiple myeloma who have undergone chimeric antigen receptor T-cell (CAR T) therapy. It aims to establish a diverse cohort of patients receiving this treatment at Moffitt Cancer Center, focusing on both clinical outcomes and psychosocial factors such as anxiety and social support. By evaluating the relationship between these factors and patient health-related quality of life, the research seeks to provide insights that could improve care for this patient population.
Why it matters
Potential benefit: If successful, this research could enhance the understanding of how CAR T therapy impacts the overall well-being and quality of life of multiple myeloma patients.
How similar studies have gone: Previous research has shown promising results with CAR T therapy in multiple myeloma, indicating that this approach has the potential for significant clinical impact.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Oswald, Laura B. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Oswald, Laura B.
Related research
Other NIH-funded projects on the same topics.
-
Survivorship in Multiple Myeloma Patients Treated with CAR T-Cell Therapy
This study looks at real-world experiences and well-being of people with multiple myeloma who received CAR T-cell therapy, focusing on their symptoms, mood, and quality of life.
-
Life after CAR T for multiple myeloma
This project will follow people with relapsed or refractory multiple myeloma who received CAR T to learn about their symptoms, quality of life, and immune changes after treatment.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.